Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › treosulfan

treosulfan

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of treosulfan

4 trials tracked of treosulfan.

4Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4
  1. Phase 2 Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders Completed
  2. Phase 2 Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Completed
  3. Phase 2 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Completed
  4. Phase 2 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients
Hematology RCT
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients Treosulfan Shows Better Outcomes for Patients with Acute Myeloid Leukemia
This Phase 3 randomized trial subgroup analysis of 352 patients with AML undergoing alloHCT found treosulfan-fludarabine superior to reduced…
A new analysis of a Phase 3 trial suggests treosulfan may offer better survival rates and fewer complications for patients with acute myeloi…
Sep 1, 2026
Meta-analysis of HSCT with treosulfan in Ataxia Telangiectasia patients shows mixed survival outcomes and significant toxicities
Hematology Meta-analysis
Meta-analysis of HSCT with treosulfan in Ataxia Telangiectasia patients shows mixed survival outcomes and significant toxicities A Teen With a Rare Disease Beat Leukemia After a Risky Transplant
This systematic review and meta-analysis evaluated hematopoietic stem cell transplantation (HSCT) using treosulfan in 16 patients with Ataxi…
A 16-year-old with a rare genetic disease survived leukemia after a tailored stem cell transplant, offering new hope for others with this fr…
Frontiers Apr 16, 2026